San Diego, CA, October 15, 2024 – Nucleus Biologics, a leading provider of cell culture and bioprocessing solutions for the cell and gene therapy (CGT) industry, has launched NB-KUL DF, a DMSO-free, chemically-defined cryomedia set to redefine cryopreservation standards. Designed for CGT manufacturers, NB-KUL DF matches DMSO-based media performance and outperforms other DMSO-free options in cell viability, recovery, and expansion. While DMSO is an effective cryoprotectant, its toxicity compromises cell viability, can cause patient issues, and requires complex wash steps, adding cost and variability. NB-KUL DF eliminates these issues, offering a DMSO-free solution that preserves cell integrity, eliminates the potential for patient side effects, and simplifies cryopreservation making it ideal for T cells, MSCs, and other sensitive cell types used in CGT. [Read more…]
Stem Cell Fillings Replace The Need For Root Canal Procedure
Those who live in fear of the infamous root canal – maligned worldwide for its painful nature and disliked for the fact that it kills the tooth – will find relief in the news that researchers have found a promising alternative in the form of stem cell fillings. This approach relies on treating root causes and conditions (no pun intended) rather than treating surface symptoms. The goal of regenerative medicine? To return former functionality to the body – in this case, the tooth.
The goal behind stem cell fillings is to repair the tooth as though the damage had never occurred. Of course, this approach raises many questions. How is it different than a root canal? Where do you get the stem cells? Are there risks involved? The goal of this article is to answer these questions. [Read more…]
AABB Releases New Resources and Initiatives For its Certified Advanced Biotherapies Professional (CABP) Program
Oct 11, 2024, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce several new offerings as part of its Certified Advanced Biotherapies Professional (CABP) credentialing program. These updates, released to make the CABP program more accessible to biotherapies professionals and organizations, include:
• CABP Exam Prep Bootcamps Video Series [Read more…]
Cell X Technologies and Aspen Neuroscience collaborate to address throughput and scalability in manufacturing automation to facilitate iPSC cell processing
Advancing the promise of cell-replacement therapy for people with Parkinson’s disease
CLEVELAND, Ohio / SAN DIEGO, Calif. – October 8, 2024 – Cell X Technologies, pioneers in automated cell processing solutions, and Aspen Neuroscience, Inc., dedicated to autologous regenerative medicine, have entered into a collaboration and licensing agreement focused on providing an automated solution for Aspen’s iPSC-derived autologous clinical manufacturing. [Read more…]
GC Therapeutics Emerges with $75M and Star-Studded Leadership to Launch Off-the-Shelf iPSC-Derived Cell Therapies at Scale
A new and highly capitalized market player has boldly declared its debut as a developer of allogeneic, off-the-shelf iPCS-derived cell therapeutics. GC Therapeutics (GCTx) has officially launched, bringing with it a revolutionary approach to cell therapy that aims to overcome current challenges in scalability, efficiency, and cost-effectiveness that have traditionally hindered the development of iPSC-derived therapies. With the debut of its innovative TFome™ platform, GCTx is positioned to scale the full potential of induced pluripotent stem cell (iPSC)-based therapies. [Read more…]
- « Previous Page
- 1
- …
- 52
- 53
- 54
- 55
- 56
- …
- 201
- Next Page »